AstraZeneca PLC AZN NYSE

AstraZeneca PLC (AZN) generated $14.58B in operating cash flow for fiscal year 2025. After capital expenditures of $2.81B, free cash flow was $11.77B.

Free cash flow margin was 20% of revenue. Cash conversion ratio was 1.43x, indicating earnings are backed by cash.

The company returned $5.08B in dividends and $719.66M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (94/100, Pass) — $11.77B (20% FCF margin) supports a durable competitive advantage
• INCOME (70/100) — Cash conversion ratio was 1.43x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.